Services

Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.

Sectors

Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

What next for biotech patenting in Australia?


4th Jan 2016

In its recent D’Arcy v Myriad Genetics Inc (Myriad) decision, the Australian High Court ruled that claims directed to isolated BRCA nucleic acids were patent ineligible. Since then there has been much speculation on how this decision would be interpreted by the Australian Patent Office. In particular, many in the industry were concerned that the Australian Patent Office would, by analogy to developments at the US Patent and Trademark Office (USPTO), extend the court’s findings to exclude all isolated biological materials.

Following public consultation, new examination guidelines have been issued by the Australian Patent Office, which apply immediately to pending applications. These guidelines state that “the law is to be applied on a case by case basis taking into account the principles and approach taken by the High Court“, and that it is useful for Examiners to ask:

  1. What is the substance of the claim (not merely its form)?
  2. Has the substance of the claim been “made” or changed by man, or is it “artificial”?
  3. Does the invention have economic utility?
  4. Does the invention as claimed represent a new class of claim?

Based on Myriad, the guidelines state that isolated naturally occurring nucleic acids1 are excluded from patentability. In addition, the following nucleic acids are excluded where they “merely replicate the genetic information of a naturally occurring organism“: cDNA and synthetic nucleic acids, probes and primers and isolated interfering/inhibitory nucleic acids. However, the guidelines state that “Subject matter of this type may be patentable where utility of the invention lies in genetic information that has been “made” “(e.g. non-naturally occurring chimeric nucleic acid)“.

The guidelines also provide examples of biotech inventions that are not excluded from patentability, namely: recombinant or isolated proteins, pharmaceuticals and other chemical substances, methods of treatment, methods of applying herbicides and applications of computer technology. The guidelines also note that there are significant factors supporting eligibility of plants and micro-organisms.

Patent applicants will, on the one hand, be relieved that the Australian Patent Office has not excluded all isolated biological materials from patentability. However, on the other hand, the ban on patenting isolated naturally-occurring nucleic acids will make the protection of biotech inventions more challenging in Australia. It will be interesting to see how these guidelines are implemented by examiners as well as how the case law develops over the coming years.

This article is for general information only. Its content is not a statement of the law on any subject and does not constitute advice. Please contact Reddie & Grose LLP for advice before taking any action in reliance on it.

Register for notifications
Enter your email address here to receive our monthly bulletin of IP news and developments.
    Please read our privacy notice.
Saved Staff
Staff member

Remove all

Saved profiles
Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162